SUN PHARMA Q4 MARGINS
TCS, Infy power D-Street to fresh record highs! Sensex soars 900 points, Nifty tops 24,500 for the first time
Indian markets rose Friday, led by TCS's strong June quarter. Sensex climbed 281 points, Nifty50 up 93 points. Stocks like TCS, Infosys, and Adani Ports surged. Maruti fell. US inflation data raised September Fed rate cut chances, noted by CME FedWatch. RBI's Das predicted 5% retail inflation. Powell's testimony hinted at possible rate cuts.
Q1 Earnings Preview: Flat to 4% growth in net profit expected from Nifty pack; auto, financials, health to outperform
Motilal Oswal and Kotak Mahindra differ in their Q2 earnings projections for the Nifty universe. While Kotak forecasts a nearly flat growth of 0.6%, Motilal Oswal projects a 4% increase in net profits. Both firms predict stronger growth when excluding global commodities. Motilal Oswal anticipates a 10% YoY increase for the Nifty excluding oil & gas and metals, while Kotak forecasts a 9.3% rise excluding oil marketing companies.
Mundane Monday: Sensex, Nifty settle on flat note in muted trade
Profit-taking, weak Asia cues drag markets lower. ITC, RIL gains were not enough to counter HDFC Bank, Titan drag. In sectoral performance, Nifty Bank, Auto, Media, Metal, Pharma, Realty, and Consumer Durables ended lower, while Nifty FMCG, IT, and Oil & Gas closed higher. Among individual stocks, PC Jeweller surged to lock in the 10% upper circuit after receiving approval from Punjab National Bank (PNB) for a one-time settlement of its outstanding dues.
Time to buy pharma? 3 stocks Forum Parekh is betting on
Zydus Life's US business is going to report a good set of numbers. Also, in India, wellness products are doing good, Overall Zydus Life will tend to report some 25% EBITDA margin. Therefore, Sharekhan By BNP Paribas has a buy call on Zydus Life with a price target of almost Rs 1200, says Foram Parekh
Hot stocks: Brokerage take on L&T Finance, Bajaj Finance, Gujarat Gas, Sun Pharma, and others
Brokerage firms such as UBS have maintained a buy rating on L&T Finance, while JP Morgan maintained an overweight rating on Bajaj Finance, Citi has initiated coverage on Indegene and maintained a sell rating on Gujarat Gas.
India Inc exits FY24 on a strong note, clocks double-digit profit growth in Q4
Corporate India saw double-digit growth in net profit and single-digit revenue increase in the March 2024 quarter. Expectations are for healthy growth in the current fiscal year due to peaking interest rates and government policy continuity.
- Go To Page 1
Ahead of June 4, be relatively light & in cash; curtail trading: Dipan Mehta
Dipan Mehta advises caution and light trading ahead of the upcoming election dates. He emphasizes the importance of being in cash and watching the election results closely for investment decisions.
Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 results
Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.
Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY
Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.
Sun Pharma shares tumble 5% but brokerages raise target up to Rs 1,785. Should you buy, sell or hold?
In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.
Gland Pharma Q4 Results: Net profit more than doubles to Rs 192.4 crore
The company declared its first-ever post-listing dividend of Rs 20 per equity share for FY24.
Gland Pharma Q4 Results: Firm misses profit view on higher employee costs
Indian generic injectables maker Gland Pharma reported fourth-quarter profit below estimates on Wednesday, as soaring employee expenses outweighed strong demand in its core markets.
Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24
Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.
Strides Pharma Q4 Results: Pharma co reports Rs 10.4 crore net profit
Strides Pharma Science posted a net profit of Rs 10.4 crore in Q4FY24, rebounding from a loss of Rs 1 crore in the same period last year. Pre-tax profit was Rs 29.6 crore.
Sun Pharma Q4 Results: Profit jumps 34% YoY to Rs 2,654 crore, meets Street estimates
Sun Pharma Q4 Results: The company's revenue rose 10% year-on-year to Rs 11,983 crore in the reporting quarter. It was Rs 10,931 crore a year ago. Its board has approved a final dividend of Rs 5 per share, which will be paid within the prescribed timeline. India formulations sales were Rs 3,707 crore for the fourth quarter, showing growth of 10% over Q4 last year and accounted for 31.4% of total consolidated sales for the quarter.
Q4 results today: Sun Pharma, Nykaa, Paytm among 162 companies to declare earnings on Wednesday
162 companies to report Q4 earnings on Wednesday. Nykaa expects 24% BPC and Fashion GMV growth, while Paytm faces a revenue decline from RBI actions. Analysts also predict pressure from discounting and lower advertising income.
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi's lab will be releasing their March quarter report cards this week.
JB Pharma Q4 Results: Net profit jumps 43% YoY to Rs 126 crore
The Mumbai-based company reported operating earnings before interest, taxes, depreciation and amortisation (EBITDA) at Rs 210 crore, up from Rs 181 crore in the year-ago period. The operating EBITDA margin improved 60 basis points YoY to 24.4%.
Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 crore
Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.
Piramal Pharma shares soar 11%, hit 52-week high after Q4 profit jumps 102% YoY
The company's revenue from operations increased by 18% to Rs 2,552.4 crore as against Rs 2,163.6 crore in the corresponding period of the preceding fiscal.
Q4 results today: Tata Motors, Cipla among 87 companies to announce earnings
Q4 results today: Several other companies scheduled to release their financial results include Cholamandalam Finance, Eicher Motors, Finolex Industries, Jupiter LifeLine Hospitals, Kalyan Jewellers, Piramal Pharma, Punjab and Sind Bank, Spencers Retail, TCI Express, Thermax, and more.
Cipla Q4 Results Preview: Profit may rise up to 71% YoY on healthy operations
Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by as much as 71% year-on-year, alongside an expected 7% year-on-year increase in net sales.
Alembic Pharma Q4 Results: Posts higher profit on strong N.America sales
Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.
Q4 results today: SBI, Asian Paints among 69 companies to announce earnings
Q4 results today: On Thursday, State Bank of India (SBI), the foremost public sector lender in India, will be among the 69 companies set to unveil their financial results for the quarter ending March 2024. Investors will also keep a close eye on companies like Asian Paints, BPCL, and Indian Overseas Bank as they announce their results.
Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?
Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North America as well as emerging markets. DRL’s revenue also increased 12% YoY to Rs 7,083 crore.
Q4 results today: PB Fintech, Dr Reddy's among 43 companies to announce results
Q4 results today: 43 companies are set to announce Q4 results, with Dr Reddy's and PB Fintech in focus. Dr Reddy's eyes revenue and net profit growth, while PB Fintech anticipates 18% YoY growth in core business premium.
Ajanta Pharma shares jump over 13% on strong Q4 results, buyback plans
Ajanta Pharma shares jumped 13% to Rs 2,532 in Friday's trade on BSE after the firm's consolidated net profit increased 66% year-on-year (YoY) to Rs 203 crore in the March quarter, aided by robust sales across domestic and international markets. The drug maker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal.
Adani Enterprises, TCS among 5 largecaps that saw decline in Q4 promoter pledge
Pledging of shares is one of the options that the promoters of companies use to secure loans to meet working capital requirements, personal needs and fund other ventures or acquisitions. A promoter shareholding in a company is used as collateral to avail of a loan. Here's is a list of 5 largecap stocks from the Nifty200 index firms where promoter pledge declined in Q4 FY24, according to StockEdge data:
Q4 preview: 6 companies likely to report doubling of sales. Do you own any?
6 companies expected to double sales in Q4 with sectors like automobiles, banks, gas utilities, pharmaceuticals showing YoY sales growth. Sunteck Realty set for a significant jump in net sales.
Load More
